We are live on ! Find out more
BLCM

Bellicum Pharmaceuticals, Inc.

Delisted

BLCM was delisted on the 1st of June, 2023.

96 hedge funds and large institutions have $263M invested in Bellicum Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

210% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 10

59% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 22

20% more funds holding

Funds holding: 8096 (+16)

1% less capital invested

Capital invested by funds: $266M → $263M (-$2.99M)

79% less call options, than puts

Call options by funds: $350K | Put options by funds: $1.69M

Holders
96
Holders Change
+16
Holders Change %
+20%
% of All Funds
2.39%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
31
Increased
35
Reduced
22
Closed
10
Calls
$350K
Puts
$1.69M
Net Calls
-$1.34M
Net Calls Change
-$1.31M
Name Holding Trade Value Shares
Change
Change in
Stake
VKH
101
Virtu KCG Holdings
New York
-$203K -1,489 Closed
Squarepoint
102
Squarepoint
New York
-$147K -1,079 Closed
Jane Street
103
Jane Street
New York
-$145K -1,064 Closed
NIT
104
NumerixS Investment Technologies
British Columbia, Canada
-$68K -500 Closed
Russell Investments Group
105
Russell Investments Group
United Kingdom
-$57K -412 Closed
HCM
106
Highlander Capital Management
New Jersey
-$16K -120 Closed
Group One Trading
107
Group One Trading
Illinois
-$10.5K -80 Closed

BLCM Hedge Fund Activity: Q1 2017 in Review

96 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q1 2017, worth a combined $263M — down 1.1% from $266M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new BLCM positions and 10 closed out — a net gain of 21 holders — while 35 added to existing stakes and 22 trimmed.

The largest buyer was BlackRock, adding an estimated $21.9M. The largest seller was First Eagle Investment Management, exiting entirely with an estimated $10.6M sold.

  • 96 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q1 2017, up from 80 in Q4 2016.
  • Funds reported $263M of Bellicum Pharmaceuticals, Inc. stock for Q1 2017, down 1.1% quarter-over-quarter.
  • 31 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q1 2017 and 10 closed out, a net change of +21 holders.
  • The largest Bellicum Pharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $21.9M added.
  • The largest Bellicum Pharmaceuticals, Inc. seller in Q1 2017 was First Eagle Investment Management, an estimated $10.6M sold.

Based on aggregated 13F filings for Q1 2017.